Ranbaxy Sues US FDA For Withdrawing Approval For Its Drugs
Advertisement
Advertisement
Advertisement
In its petition, Ranbaxy said that the FDA had exceeded its jurisdiction by revoking the approvals which were granted a few years ago. Ranbaxy called the FDA's decision "arbitrary, capricious and contrary to law." It added, "FDA has no power to correct an alleged 'mistake' it made six years ago".
FDA had withdrawn its approvals, saying it had made a mistake in granting them. Ranbaxy had sought FDA’s approval for the drugs manufactured at its
The FDA, while revoking its approvals, said, “Ranbaxy forfeited its eligibility for 180-day exclusivity for generic Valcyte but was silent on whether the company had also surrendered its exclusivity rights for generic Nexium. Ranbaxy in its plea has assumed that its exclusivity for Nexium is most likely to meet a similar fate.”
Advertisement
- “Wish to follow in the footsteps of PM Modi!” ‘Anupamaa’ star Rupali Ganguly joins BJP
- “Wish to follow in the footsteps of PM Modi!” ‘Anupamaa’ star Rupali Ganguly joins BJP
- Assassin’s Creed Mirage on iPhone 15: Killer game to debut on Pro and iPad on June 6
- 5 worst cooking oils for your health
- From fiber to protein: 10 health benefits of including lentils in your diet
- Nothing Phone (2a) blue edition launched
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market